Progress of hearing loss in neurofibromatosis type 2: implications for future management

被引:18
作者
Kontorinis, Georgios [1 ,2 ]
Nichani, Jaya [1 ]
Freeman, Simon R. [1 ]
Rutherford, Scott A. [3 ]
Mills, Samantha [4 ]
King, Andrew T. [3 ]
Mawman, Deborah [1 ]
Huson, Sue [5 ]
O'Driscoll, Martin [1 ]
Gareth Evans, D. [5 ]
Lloyd, Simon K. W. [1 ,6 ,7 ]
机构
[1] Cent Manchester Univ Hosp, NHS Fdn Trust, Univ Dept Otolaryngol, Manchester M13 9PL, Lancs, England
[2] Southern Teaching Hosp, Inst Neurosci, Dept Otolaryngol, Glasgow, Lanark, Scotland
[3] Salford Royal NHS Fdn Trust, Dept Neurosurg, Manchester, Lancs, England
[4] Salford Royal NHS Fdn Trust, Dept Neuroradiol, Manchester, Lancs, England
[5] Cent Manchester Univ Hosp, NHS Fdn Trust, Dept Med Genet, Manchester M13 9PL, Lancs, England
[6] Univ Manchester, Sch Canc, Manchester M13 9PL, Lancs, England
[7] Univ Manchester, Enabling Serv, Manchester M13 9PL, Lancs, England
关键词
Conservative treatment; Deafness; Neurofibromatosis type 2; Tumour size; Vestibular schwannoma; Watch wait rescan protocol; VESTIBULAR SCHWANNOMAS; NATURAL-HISTORY; CONSERVATIVE MANAGEMENT; COCHLEAR IMPLANTATION; UNITED-KINGDOM; GROWTH; PRESERVATION; NF2;
D O I
10.1007/s00405-014-3317-7
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
The objective of this study was to describe changes in hearing over time in patients with neurofibromatosis type 2 (NF2) treated conservatively. A retrospective case review was conducted in a tertiary referral centre. Pure tone audiometry, speech discrimination scores, serviceable hearing (American Academy of Otolaryngology class A or B) and measurement of vestibular schwannoma (VS) size on magnetic resonance imaging were evaluated in 56 patients (89 ears) with NF2 with at least one conservatively managed VS. Over a mean follow-up period of 7 years (range 0.8-21 years) pure tone average thresholds increased gradually with a mean annual rate of 1.3 dB for the right ear (p = 0.0003) and 2 dB for the left ear (p = 0.0009). Speech discrimination scores dropped with an average annual rate of 1.3 and 0.34 % in the right and left ear, respectively. Patients maintained serviceable hearing for an average of 7.6 years (range 2.7-19.3 years). The average annual VS growth was 0.4 mm without any correlation with hearing loss. There was a correlation between patients' age and pure tone threshold increase (p < 0.05 for both ears). In this selected population of patients with NF2, hearing threshold increases were very slow. In NF2 patients with indolently behaving tumours, serviceable hearing can be maintained for a significant length of time, making conservative management an attractive option.
引用
收藏
页码:3143 / 3150
页数:8
相关论文
共 50 条
  • [41] Current progress in genomics and targeted therapies for neurofibromatosis type 2
    Hiruta, Ryo
    Saito, Kiyoshi
    Bakhit, Mudathir
    Fujii, Masazumi
    FUKUSHIMA JOURNAL OF MEDICAL SCIENCE, 2023, 69 (02) : 95 - 103
  • [42] Clinical management and progress in sudden sensorineural hearing loss during pregnancy
    Xie, Shaobing
    Wu, Xuewen
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (02)
  • [43] Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas
    Blakeley, Jaishri O.
    Ye, Xiaobu
    Duda, Dan G.
    Halpin, Chris F.
    Bergner, Amanda L.
    Muzikansky, Alona
    Merker, Vanessa L.
    Gerstner, Elizabeth R.
    Fayad, Laura M.
    Ahlawat, Shivani
    Jacobs, Michael A.
    Jain, Rakesh K.
    Zalewski, Christopher
    Dombi, Eva
    Widemann, Brigitte C.
    Plotkin, Scott R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (14) : 1669 - U220
  • [44] Clinical course and management of intracranial meningiomas in neurofibromatosis type 2 patients
    Nowak, Arkadiusz
    Dziedzic, Tomasz
    Czernicki, Tomasz
    Kunert, Przemyslaw
    Marchel, Andrzej
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2015, 49 (06) : 367 - 372
  • [45] Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2.
    Nieder, Carsten
    STRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 (04) : 239 - 240
  • [46] Cochlear implant in type 2 neurofibromatosis: an option for better hearing rehabilitation
    Cruz, Oswaldo Laercio M.
    Vellutini, Eduardo A. S.
    BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY, 2011, 77 (04) : 538 - 538
  • [47] Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]
    Evans, D. Gareth R.
    GENETICS IN MEDICINE, 2009, 11 (09) : 599 - 610
  • [48] Natural history of vestibular schwannomas and hearing loss in NF2 patients
    Peyre, M.
    Bernardeschi, D.
    Sterkers, O.
    Kalamarides, M.
    NEUROCHIRURGIE, 2018, 64 (05) : 342 - 347
  • [49] Management of Neurofibromatosis Type 2 Associated Vestibular Schwannomas
    Huan Jia
    Ghizlene Lahlou
    Hao Wu
    Olivier Sterkers
    Michel Kalamarides
    Current Otorhinolaryngology Reports, 2021, 9 : 170 - 176
  • [50] Management of spinal tumors in neurofibromatosis type 2 patients
    Nowak, Arkadiusz
    Dziedzic, Tomasz
    Czernicki, Tomasz
    Kunert, Przemyslaw
    Marchel, Andrzej
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2016, 50 (01) : 31 - 35